Combination of HER2-Targeted Antibodies (Trastuzumab plus Pertuzumab) is Effective Against HER2 Amplified Ovarian Cancer Xenograft Models

被引：0
|
作者：
Langdon, S. P. [1 ]
Sims, A. H. [1 ]
Harrison, D. J. [2 ]
机构：
[1] Univ Edinburgh, Edinburgh, Midlothian, Scotland
[2] Univ St Andrews, St Andrews, Fife, Scotland
来源：
JOURNAL OF PATHOLOGY | 2013年 / 231卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：25 / 25
页数：1
相关论文
共 50 条
  • [41] HER2-targeted therapy-antibodies and beyond
    Fehm, Tanja
    Mueller, Volkmar
    GYNAKOLOGE, 2021, 54 (05): : 320 - 328
  • [42] CLINICAL EVALUATION OF PERTUZUMAB, A NEW HER2 TARGETED AGENT, IN BREAST CANCER
    Sasaki, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 18 - 18
  • [43] Enhanced binding at fever temperatures of HER2 in complex with trastuzumab and pertuzumab
    Singh, Puneet K.
    Stan, Razvan C.
    IMMUNOTHERAPY, 2023, 15 (13) : 1021 - 1027
  • [44] Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
    Scheuer, Werner
    Friess, Thomas
    Burtscher, Helmut
    Bossenmaier, Birgit
    Endl, Josef
    Hasmann, Max
    CANCER RESEARCH, 2009, 69 (24) : 9330 - 9336
  • [45] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [46] 225Ac-Pertuzumab Enhances Efficacy Against a Trastuzumab/Pertuzumab Resistant HER2-Positive Breast Cancer Xenograft Model
    Khan, B.
    Sanaulla, F.
    Khan, M.
    Karkare, S.
    Causey, P.
    Perron, R.
    Gendron, D.
    Fonge, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S649 - S649
  • [47] Patient-derived xenograft (PDX) models expressing HER2 reflect clinical responses to targeted HER2 inhibition
    Ciznadija, Daniel
    Sonnenblick, Amir
    Jaskowiak, Jennifer
    Davies, Angela
    Sidransky, David
    CANCER RESEARCH, 2017, 77
  • [48] HER2-targeted therapies in gastric cancer
    Zhu, Yinxing
    Zhu, Xuedan
    Wei, Xiaowei
    Tang, Cuiju
    Zhang, Wenwen
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1876 (01):
  • [49] HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer
    Xu, Xiaowei
    De Angelis, Carmine
    Burke, Kathleen A.
    Nardone, Agostina
    Hu, Huizhong
    Qin, Lanfang
    Veeraraghavan, Jamunarani
    Sethunath, Vidyalakshmi
    Heiser, Laura M.
    Wang, Nicholas
    Ng, Charlotte K. Y.
    Chen, Edward S.
    Renwick, Alexander
    Wang, Tao
    Nanda, Sarmistha
    Shea, Martin
    Mitchell, Tamika
    Rajendran, Mahitha
    Waters, Ian
    Zabransky, Daniel J.
    Scott, Kenneth L.
    Gutierrez, Carolina
    Nagi, Chandandeep
    Geyer, Felipe C.
    Chamness, Gary C.
    Park, Ben H.
    Shaw, Chad A.
    Hilsenbeck, Susan G.
    Rimawi, Mothaffar F.
    Gray, Joe W.
    Weigelt, Britta
    Reis-Filho, Jorge S.
    Osborne, C. Kent
    Schiff, Rachel
    CLINICAL CANCER RESEARCH, 2017, 23 (17) : 5123 - 5134
  • [50] Evaluation of HER-2 positive breast cancer treated with dual-targeted treatment of trastuzumab plus pertuzumab
    Jiang, Shuai
    Geng, Shuai
    Gao, Xinyue
    Liu, Tong
    Luo, Xinyu
    Wang, Nan
    Shi, Ning
    Dong, Mei
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2023, 45 (05) : 616 - 625
12345